A Randomized, Double Blind Study to Compare the Effects of Aleglitazar and Actos on Glomerular Filtration Rate and Other Parameters of Renal Function in Patients With Type 2 Diabetes.
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2016
At a glance
- Drugs Aleglitazar (Primary) ; Pioglitazone
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms SESTA-R
- Sponsors Roche
- 31 Aug 2018 Biomarkers information updated
- 01 Sep 2011 Results published in the International Journal of Cardiology.
- 20 May 2009 Actual end date changed from Nov 2008 to Apr 2009 as reported by ClinicalTrials.gov.